Weight Loss In Obese Subjects Taking Either GW869682 Or Placebo 3 Times Per Day For 12 Weeks

Phase 2

Completed

• Conditions: Obesity

• Registration Number: NCT00297180
• Lead Sponsor: GlaxoSmithKline

Brief Summary

GW869682 causes glucose to be excreted in the urine. The purpose of this study is to see whether enough calories from glucose are excreted in the urine to cause weight loss.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2006-01
• Study First Submitted: 2006-02-24
• Study First Submitted QC: 2006-02-24
• Study First Posted: 2006-02-28
• Primary Completion: 2006-09
• Study Completion: 2006-09
• Status Verified: 2015-04
• Last Update Submitted: 2015-04-14
• Last Update Posted: 2015-04-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 136

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Percentage change in body weight from baseline to Week 12.	from baseline to Week 12.

Secondary Outcome Measures

Name	Time	Method
Blood levels of GW869682 at the Week 2 and Week 11.	at the Week 2 and Week 11

Trial Locations

Locations (1)

GSK Investigational Site; 🇺🇸 Portland, Oregon, United States